ARQT's Quality Score rose 2 points on Wed, Nov 4, to 21.
Follow ARQT's trial news. Pro members can get an alert when Arcutis Biotherapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 1,212% over three years while the S&P 500 rose 80%.
“Sequential growth was driven by increasing demand across products, the launch of ZORYVE foam 0.3% in plaque psoriasis of the scalp and body”
| The company | Sales up 76% on the year |
| Its score | Up:Up to Exceptional for the first time since at least Oct 2021 |
| Latest filing | 8-K, Nov 4 |
ReportToday after the close: sales of $143.9M; a profit of $0.06 a share. Raised its outlook for the year. Past reports ›
After hoursArcutis Biotherapeutics reported quarterly revenue of $143.9 million and diluted EPS of $0.06
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
Expected to report Wed Feb 24, after the close
Director Howard G. Welgus sold 4,728 shares on Oct 15, under a planned sale. 37 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ARQT scores 21 today, against a median of 14.5 over its last 20 recorded sessions.
ARQT is #3 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Share count against a year before: ARQT +2.8%, AUPH -3.6%, ZYME -3.1%, PTCT +6.2%.
Expected to report Wed Feb 24, after the close (in 112 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $143.9M, 45% more than a year ago; a profit of $0.06 a share, from $0.06.
“The year-over-year and quarter-over-quarter increases were predominantly due to increased unit demand, as well as modest improvements in gross-to-net (GTN) deductions.”
ARQT's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Net product sales | $535M to $545M |
“The year-over-year and sequential increases were driven by increasing demand across products .”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | +7.8% | -2.5% | -3.0% |
| May 6, 2026 | -5.6% | -14.5% | -10.3% |
| Feb 25, 2026 | +2.5% | +5.8% | -10.7% |
Sales grew every year from 2022 to 2025, to $376M. It lost money in each of the four years.
2 insiders sold $1.4M across 6 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ARQT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
“The biotechnology and pharmaceutical industry is highly competitive, and is characterized by rapid and significant changes, intense competition, and a bias towards proprietary products.”
ARQT scores 21 today, which Breakaway calls Exceptional. It is #3 of 291 in Biotech by Quality Score, with 9 of 14 chart checks firing. Up 1,212% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ARQT scores 21 today, which Breakaway calls Exceptional (20 or more). That is #3 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ARQT's 21.
2 insiders sold $1.4M across 6 filings in the last 6 months. No open-market buys on record. The newest is Terrie Curran, Director, who sold $677K on Aug 27. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.